TY - JOUR
T1 - Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015
T2 - A systematic analysis from the Global Burden of Disease Study 2015
AU - GBD 2015 Tobacco Collaborators
AU - Reitsma, Marissa B.
AU - Fullman, Nancy
AU - Ng, Marie
AU - Salama, Joseph S.
AU - Abajobir, Amanuel
AU - Abate, Kalkidan Hassen
AU - Abbafati, Cristiana
AU - Abera, Semaw Ferede
AU - Abraham, Biju
AU - Abyu, Gebre Yitayih
AU - Adebiyi, Akindele Olupelumi
AU - Al-Aly, Ziyad
AU - Aleman, Alicia V.
AU - Ali, Raghib
AU - Al Alkerwi, Ala'a
AU - Allebeck, Peter
AU - Al-Raddadi, Rajaa Mohammad
AU - Amare, Azmeraw T.
AU - Amberbir, Alemayehu
AU - Ammar, Walid
AU - Amrock, Stephen Marc
AU - Antonio, Carl Abelardo T.
AU - Asayesh, Hamid
AU - Atnafu, Niguse Tadela
AU - Azzopardi, Peter
AU - Banerjee, Amitava
AU - Barac, Aleksandra
AU - Barrientos-Gutierrez, Tonatiuh
AU - Basto-Abreu, Ana Cristina
AU - Bazargan-Hejazi, Shahrzad
AU - Bedi, Neeraj
AU - Bell, Brent
AU - Bello, Aminu K.
AU - Bensenor, Isabela M.
AU - Beyene, Addisu Shunu
AU - Bhala, Neeraj
AU - Biryukov, Stan
AU - Bolt, Kaylin
AU - Brenner, Hermann
AU - Butt, Zahid
AU - Cavalleri, Fiorella
AU - Cercy, Kelly
AU - Chen, Honglei
AU - Christopher, Devasahayam Jesudas
AU - Ciobanu, Liliana G.
AU - Colistro, Valentina
AU - Colomar, Mercedes
AU - Cornaby, Leslie
AU - Dai, Xiaochen
AU - Damtew, Solomon Abrha
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - Dansereau, Emily
AU - Davletov, Kairat
AU - Dayama, Anand
AU - Degfie, Tizta Tilahun
AU - Deribew, Amare
AU - Dharmaratne, Samath D.
AU - Dimtsu, Balem Demtsu
AU - Doyle, Kerrie E.
AU - Endries, Aman Yesuf
AU - Ermakov, Sergey Petrovich
AU - Estep, Kara
AU - Faraon, Emerito Jose Aquino
AU - Farzadfar, Farshad
AU - Feigin, Valery L.
AU - Feigl, Andrea B.
AU - Fischer, Florian
AU - Friedman, Joseph
AU - G/hiwot, Tsegaye Tewelde
AU - Gall, Seana L.
AU - Gao, Wayne
AU - Gillum, Richard F.
AU - Gold, Audra L.
AU - Gopalani, Sameer Vali
AU - Gotay, Carolyn C.
AU - Gupta, Rahul
AU - Gupta, Rajeev
AU - Gupta, Vipin
AU - Hamadeh, Randah Ribhi
AU - Hankey, Graeme
AU - Harb, Hilda L.
AU - Hay, Simon I.
AU - Horino, Masako
AU - Horita, Nobuyuki
AU - Hosgood, H. Dean
AU - Husseini, Abdullatif
AU - Ileanu, Bogdan Vasile
AU - Islami, Farhad
AU - Jiang, Guohong
AU - Jiang, Ying
AU - Jonas, Jost B.
AU - Kabir, Zubair
AU - Kamal, Ritul
AU - Kasaeian, Amir
AU - Kesavachandran, Chandrasekharan Nair
AU - Khader, Yousef S.
AU - Khalil, Ibrahim
AU - Khang, Young Ho
AU - Khera, Sahil
AU - Khubchandani, Jagdish
AU - Kim, Daniel
AU - Kim, Yun Jin
AU - Kimokoti, Ruth W.
AU - Kinfu, Yohannes
AU - Knibbs, Luke D.
AU - Kokubo, Yoshihiro
AU - Kolte, Dhaval
AU - Kopec, Jacek
AU - Kosen, Soewarta
AU - Kotsakis, Georgios A.
AU - Koul, Parvaiz A.
AU - Koyanagi, Ai
AU - Krohn, Kristopher J.
AU - Krueger, Hans
AU - Defo, Barthelemy Kuate
AU - Bicer, Burcu Kucuk
AU - Kulkarni, Chanda
AU - Kumar, G. Anil
AU - Leasher, Janet L.
AU - Lee, Alexander
AU - Leinsalu, Mall
AU - Li, Tong
AU - Linn, Shai
AU - Liu, Patrick
AU - Liu, Shiwei
AU - Lo, Loon Tzian
AU - Lopez, Alan D.
AU - Ma, Stefan
AU - El Razek, Hassan Magdy Abd
AU - Majeed, Azeem
AU - Malekzadeh, Reza
AU - Malta, Deborah Carvalho
AU - Manamo, Wondimu Ayele
AU - Martinez-Raga, Jose
AU - Mekonnen, Alemayehu Berhane
AU - Mendoza, Walter
AU - Miller, Ted R.
AU - Mohammad, Karzan Abdulmuhsin
AU - Morawska, Lidia
AU - Musa, Kamarul Imran
AU - Nagel, Gabriele
AU - Neupane, Sudan Prasad
AU - Nguyen, Quyen
AU - Oh, In Hwan
AU - Oyekale, Abayomi Samuel
AU - PA, Mahesh
AU - Pana, Adrian
AU - Park, Eun Kee
AU - Patil, Snehal T.
AU - Patton, George C.
AU - Pedro, Joao
AU - Qorbani, Mostafa
AU - Rafay, Anwar
AU - Rahman, Mahfuzar
AU - Rai, Rajesh Kumar
AU - Ram, Usha
AU - Ranabhat, Chhabi Lal
AU - Refaat, Amany H.
AU - Reinig, Nickolas
AU - Roba, Hirbo Shore
AU - Rodriguez, Alina
AU - Roman, Yesenia
AU - Roth, Gregory
AU - Roy, Ambuj
AU - Sagar, Rajesh
AU - Salomon, Joshua
AU - Sanabria, Juan
AU - de Souza Santos, Itamar
AU - Sartorius, Benn
AU - Satpathy, Maheswar
AU - Sawhney, Monika
AU - Sawyer, Susan
AU - Saylan, Mete
AU - Schaub, Michael P.
AU - Schluger, Neil
AU - Schutte, Aletta Elisabeth
AU - Sepanlou, Sadaf G.
AU - Serdar, Berrin
AU - Shaikh, Masood Ali
AU - She, Jun
AU - Shin, Min Jeong
AU - Shiri, Rahman
AU - Shishani, Kawkab
AU - Shiue, Ivy
AU - Sigfusdottir, Inga Dora
AU - Silverberg, Jonathan I.
AU - Singh, Jasvinder
AU - Singh, Virendra
AU - Slepak, Erica Leigh
AU - Soneji, Samir
AU - Soriano, Joan B.
AU - Soshnikov, Sergey
AU - Sreeramareddy, Chandrashekhar T.
AU - Stein, Dan J.
AU - Stranges, Saverio
AU - Subart, Michelle L.
AU - Swaminathan, Soumya
AU - Szoeke, Cassandra E.I.
AU - Tefera, Worku Mekonnen
AU - Topor-Madry, Roman
AU - Tran, Bach
AU - Tsilimparis, Nikolaos
AU - Tymeson, Hayley
AU - Ukwaja, Kingsley Nnanna
AU - Updike, Rachel
AU - Uthman, Olalekan A.
AU - Violante, Francesco Saverio
AU - Vladimirov, Sergey K.
AU - Vlassov, Vasiliy
AU - Vollset, Stein Emil
AU - Vos, Theo
AU - Weiderpass, Elisabete
AU - Wen, Chi Pan
AU - Werdecker, Andrea
AU - Wilson, Shelley
AU - Wubshet, Mamo
AU - Xiao, Lin
AU - Yakob, Bereket
AU - Yano, Yuichiro
AU - Ye, Penpeng
AU - Yonemoto, Naohiro
AU - Yoon, Seok Jun
AU - Younis, Mustafa Z.
AU - Yu, Chuanhua
AU - Zaidi, Zoubida
AU - El Sayed Zaki, Maysaa
AU - Zhang, Anthony Lin
AU - Zipkin, Ben
AU - Murray, Christopher J.L.
AU - Forouzanfar, Mohammad H.
AU - Gakidou, Emmanuela
N1 - Funding Information:
Bill & Melinda Gates Foundation and Bloomberg Philanthropies. Dan J Stein reports personal fees from Lundbeck, personal fees from Novartis, personal fees from AMBRF, grants from NRGF, grants from Servier, grants from Biocodex, grants from MRC, personal fees from CIPLA, personal fees from SUN, outside the submitted work; Jasvinder Singh reports personal fees from Savient, personal fees from Takeda, personal fees from Regeneron, personal fees from Iroko, personal fees from Merz, personal fees from Bioiberica, personal fees from Crealta, personal fees from Allergan, personal fees from UBM LLC, personal fees from WebMD, personal fees from The American College of Rheuamtology, institutional grants from Takeda, and institutional grants for Savient, outside the submitted work; Marie Ng reports personal fees from IBM Watson Health, outside the submitted work; Itamar De Souza Santos reports grants from FAPESP (Brazilian public agency), outside the submitted work.
Publisher Copyright:
© 2017 The Author(s). Published by Elsevier Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2017/5/13
Y1 - 2017/5/13
N2 - Background: The scale-up of tobacco control, especially after the adoption of the Framework Convention for Tobacco Control, is a major public health success story. Nonetheless, smoking remains a leading risk for early death and disability worldwide, and therefore continues to require sustained political commitment. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) offers a robust platform through which global, regional, and national progress toward achieving smoking-related targets can be assessed. Methods: We synthesised 2818 data sources with spatiotemporal Gaussian process regression and produced estimates of daily smoking prevalence by sex, age group, and year for 195 countries and territories from 1990 to 2015. We analysed 38 risk-outcome pairs to generate estimates of smoking-attributable mortality and disease burden, as measured by disability-adjusted life-years (DALYs). We then performed a cohort analysis of smoking prevalence by birth-year cohort to better understand temporal age patterns in smoking. We also did a decomposition analysis, in which we parsed out changes in all-cause smoking-attributable DALYs due to changes in population growth, population ageing, smoking prevalence, and risk-deleted DALY rates. Finally, we explored results by level of development using the Socio-demographic Index (SDI). Findings: Worldwide, the age-standardised prevalence of daily smoking was 25·0% (95% uncertainty interval [UI] 24·2–25·7) for men and 5·4% (5·1–5·7) for women, representing 28·4% (25·8–31·1) and 34·4% (29·4–38·6) reductions, respectively, since 1990. A greater percentage of countries and territories achieved significant annualised rates of decline in smoking prevalence from 1990 to 2005 than in between 2005 and 2015; however, only four countries had significant annualised increases in smoking prevalence between 2005 and 2015 (Congo [Brazzaville] and Azerbaijan for men and Kuwait and Timor-Leste for women). In 2015, 11·5% of global deaths (6·4 million [95% UI 5·7–7·0 million]) were attributable to smoking worldwide, of which 52·2% took place in four countries (China, India, the USA, and Russia). Smoking was ranked among the five leading risk factors by DALYs in 109 countries and territories in 2015, rising from 88 geographies in 1990. In terms of birth cohorts, male smoking prevalence followed similar age patterns across levels of SDI, whereas much more heterogeneity was found in age patterns for female smokers by level of development. While smoking prevalence and risk-deleted DALY rates mostly decreased by sex and SDI quintile, population growth, population ageing, or a combination of both, drove rises in overall smoking-attributable DALYs in low-SDI to middle-SDI geographies between 2005 and 2015. Interpretation: The pace of progress in reducing smoking prevalence has been heterogeneous across geographies, development status, and sex, and as highlighted by more recent trends, maintaining past rates of decline should not be taken for granted, especially in women and in low-SDI to middle-SDI countries. Beyond the effect of the tobacco industry and societal mores, a crucial challenge facing tobacco control initiatives is that demographic forces are poised to heighten smoking's global toll, unless progress in preventing initiation and promoting cessation can be substantially accelerated. Greater success in tobacco control is possible but requires effective, comprehensive, and adequately implemented and enforced policies, which might in turn require global and national levels of political commitment beyond what has been achieved during the past 25 years.
AB - Background: The scale-up of tobacco control, especially after the adoption of the Framework Convention for Tobacco Control, is a major public health success story. Nonetheless, smoking remains a leading risk for early death and disability worldwide, and therefore continues to require sustained political commitment. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) offers a robust platform through which global, regional, and national progress toward achieving smoking-related targets can be assessed. Methods: We synthesised 2818 data sources with spatiotemporal Gaussian process regression and produced estimates of daily smoking prevalence by sex, age group, and year for 195 countries and territories from 1990 to 2015. We analysed 38 risk-outcome pairs to generate estimates of smoking-attributable mortality and disease burden, as measured by disability-adjusted life-years (DALYs). We then performed a cohort analysis of smoking prevalence by birth-year cohort to better understand temporal age patterns in smoking. We also did a decomposition analysis, in which we parsed out changes in all-cause smoking-attributable DALYs due to changes in population growth, population ageing, smoking prevalence, and risk-deleted DALY rates. Finally, we explored results by level of development using the Socio-demographic Index (SDI). Findings: Worldwide, the age-standardised prevalence of daily smoking was 25·0% (95% uncertainty interval [UI] 24·2–25·7) for men and 5·4% (5·1–5·7) for women, representing 28·4% (25·8–31·1) and 34·4% (29·4–38·6) reductions, respectively, since 1990. A greater percentage of countries and territories achieved significant annualised rates of decline in smoking prevalence from 1990 to 2005 than in between 2005 and 2015; however, only four countries had significant annualised increases in smoking prevalence between 2005 and 2015 (Congo [Brazzaville] and Azerbaijan for men and Kuwait and Timor-Leste for women). In 2015, 11·5% of global deaths (6·4 million [95% UI 5·7–7·0 million]) were attributable to smoking worldwide, of which 52·2% took place in four countries (China, India, the USA, and Russia). Smoking was ranked among the five leading risk factors by DALYs in 109 countries and territories in 2015, rising from 88 geographies in 1990. In terms of birth cohorts, male smoking prevalence followed similar age patterns across levels of SDI, whereas much more heterogeneity was found in age patterns for female smokers by level of development. While smoking prevalence and risk-deleted DALY rates mostly decreased by sex and SDI quintile, population growth, population ageing, or a combination of both, drove rises in overall smoking-attributable DALYs in low-SDI to middle-SDI geographies between 2005 and 2015. Interpretation: The pace of progress in reducing smoking prevalence has been heterogeneous across geographies, development status, and sex, and as highlighted by more recent trends, maintaining past rates of decline should not be taken for granted, especially in women and in low-SDI to middle-SDI countries. Beyond the effect of the tobacco industry and societal mores, a crucial challenge facing tobacco control initiatives is that demographic forces are poised to heighten smoking's global toll, unless progress in preventing initiation and promoting cessation can be substantially accelerated. Greater success in tobacco control is possible but requires effective, comprehensive, and adequately implemented and enforced policies, which might in turn require global and national levels of political commitment beyond what has been achieved during the past 25 years.
KW - Adolescent
KW - Adult
KW - Age Distribution
KW - Aged
KW - Aged, 80 and over
KW - Female
KW - Global Burden of Disease
KW - Global Health
KW - Humans
KW - Internationality
KW - Male
KW - Middle Aged
KW - Normal Distribution
KW - Prevalence
KW - Quality-Adjusted Life Years
KW - Retrospective Studies
KW - Risk Factors
KW - Sex Distribution
KW - Smoking/epidemiology
KW - Socioeconomic Factors
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85017146418&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)30819-X
DO - 10.1016/S0140-6736(17)30819-X
M3 - Article
C2 - 28390697
AN - SCOPUS:85017146418
SN - 0140-6736
VL - 389
SP - 1885
EP - 1906
JO - The Lancet
JF - The Lancet
IS - 10082
ER -